Company newsForm 8-K
AbCellera Biologics ABCL
AbCellera Biologics prices $200 million offering of common shares and pre-funded warrants
AbCellera Biologics said gross proceeds are expected to be approximately $200 million, before underwriting discounts and offering expenses.
GetSignal
On August 12, 2026, AbCellera Biologics priced an underwritten offering of 17,435,897 common shares at $9.75 per share, plus pre-funded warrants for up to 3,076,926 shares.
It expects net proceeds of approximately $187 million and closing on or about August 14, 2026, subject to customary closing conditions. It intends to use the proceeds for its internal pipeline including lead clinical program ABCL635 and for working capital and general corporate purposes.
Key facts
- Gross proceeds expected
- Approximately $200 million
- Net proceeds expected
- Approximately $187 million
- Expected closing
- August 14, 2026, subject to customary closing conditions
Source: Form 8-K filed August 13, 2026. The company's release as filed with the SEC.
Written by GetSignal with AI from the company's SEC filing. How we make news
Not investment advice.
More company news
AbCellera Biologics first, then the newest- AbCellera Biologics appoints Lynn Seely to its board of directors
ABCL · AbCellera Biologics · Form 8-K · Jul 6, 2026
- AbCellera Biologics shareholders elect two Class III directors
ABCL · AbCellera Biologics · Form 8-K · Jun 12, 2026
- Western Digital stockholders elect nine directors at annual meeting
WDC · Western Digital · Form 8-K · Nov 20, 2026
- Ares Capital subsidiary amends BNP Paribas funding facility
ARCC · Ares Capital · Form 8-K · Nov 20, 2026
